Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Phase IIa clinical trial to evaluate the effects of anti-retroviral therapy in Alzheimer’s disease (ART-AD)

12 Mar 2025

Abstract excerpt

Abstract Retrotransposons constitute over 40% of the human genome. Studies in Drosophila , mice, cultured cells, and human brain show that retrotransposons are activated in tauopathies, including Alzheimer’s disease, and causally drive neurodegeneration. The reverse transcriptase inhibitor 3TC (lamivudine) reduces retrotransposon activation and suppresses tau neurotoxicity among model systems. This phase 2a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced biosensing and bioanalysis techniques
Share to Alzheimer's disease research and treatments
Share to HIV Research and Treatment

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40104524
DOI: 10.1038/s44400-024-00001-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Phase IIa clinical trial to evaluate the effects of anti-retroviral therapy in Alzheimer’s disease (ART-AD)PMID 40104524Read ↗

Biologics as Therapeutical Agents Under Perspective Clinical Studies for Alzheimer’s DiseaseSemantic proximity Read ↗

Precision Medicine Treatment of Alzheimer’s Disease: Successful Randomized Controlled TrialSemantic proximity Read ↗

Human herpesvirus‐associated transposable element activation in human aging brains with Alzheimer's diseaseSemantic proximity Read ↗

Precision Medicine Treatment of Alzheimer’s Disease: Successful Randomized Controlled TrialSemantic proximity Read ↗

Endogenous recapitulation of Alzheimer’s disease neuropathology through human 3D direct neuronal reprogrammingSemantic proximity Read ↗

FDA-Approved Passive Immunization Treatments Against Aβ in Alzheimer’s Disease: Where Are We Now?Semantic proximity Read ↗

Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trialSemantic proximity Read ↗

Oral Blarcamesine Phase IIb/III Trial Confirms Identified Precision Medicine Patient Population – Significant Broad Clinical and Quality of Life Improvements for Early Alzheimer’s Disease PatientsSemantic proximity Read ↗

Genomic Factors and Therapeutic Approaches in HIV-Associated Neurocognitive Disorders: A Comprehensive ReviewSemantic proximity Read ↗

Tau-Targeting Nanoparticles for Treatment of Alzheimer's DiseaseSemantic proximity Read ↗

Reduction of human Alzheimer’s disease risk and reversal of mouse model cognitive deficit with nucleoside analog useSemantic proximity Read ↗

Nucleic Acid Liquid Biopsies in Alzheimer’s Disease: Current State, Challenges, and OpportunitiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.